title: Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer.
abstract: OBJECTIVE
  We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy.
  
  
  METHODS
  Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively.
  
  
  RESULTS
  A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT.
  
  
  CONCLUSIONS
  SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control.
authors: Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan erbb2jp@yahoo.co.jp.
authors: Tomoaki
authors: T
authors: Hakariya
authors: Department of Radiology and Radiotherapy, Nagasaki prefecture Shimabara Hospital, Nagasaki, Japan.
authors: Shiro
authors: S
authors: Obata
authors: Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors: Tsukasa
authors: T
authors: Igawa
authors: Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors: Hideki
authors: H
authors: Sakai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005240:Feasibility Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*
chemical_list: D017430:Prostate-Specific Antigen
keywords: Castration-resistant prostate cancer; intensity modulated radiation therapy; simultaneous integrated boost